Wall Street Zen upgraded shares of Greenwich LifeSciences (NASDAQ:GLSI – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.
Greenwich LifeSciences Stock Performance
GLSI opened at $22.86 on Friday. The company’s 50 day simple moving average is $25.07 and its 200 day simple moving average is $19.92. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10. The stock has a market capitalization of $316.61 million, a PE ratio of -15.66 and a beta of 1.39.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of GLSI. Bank of America Corp DE lifted its position in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after buying an additional 1,322 shares in the last quarter. Strs Ohio acquired a new position in Greenwich LifeSciences during the first quarter valued at approximately $177,000. Rhumbline Advisers lifted its position in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after buying an additional 3,168 shares in the last quarter. Geode Capital Management LLC lifted its position in Greenwich LifeSciences by 1.4% during the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after buying an additional 1,972 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Greenwich LifeSciences during the second quarter valued at approximately $509,000. 4.16% of the stock is owned by institutional investors and hedge funds.
Greenwich LifeSciences Company Profile
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.
Further Reading
- Five stocks we like better than Greenwich LifeSciences
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
